Medpace (NASDAQ:MEDP) and STARPHARMA HOLD/S (OTCMKTS:SPHRY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Volatility & Risk
Medpace has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, STARPHARMA HOLD/S has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
76.7% of Medpace shares are owned by institutional investors. 24.2% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Medpace and STARPHARMA HOLD/S, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Medpace presently has a consensus price target of $58.00, indicating a potential downside of 11.34%. Given Medpace’s higher probable upside, research analysts plainly believe Medpace is more favorable than STARPHARMA HOLD/S.
This table compares Medpace and STARPHARMA HOLD/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Medpace and STARPHARMA HOLD/S’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Medpace||$704.59 million||3.33||$73.18 million||$2.59||25.26|
|STARPHARMA HOLD/S||$3.79 million||95.79||-$7.97 million||N/A||N/A|
Medpace has higher revenue and earnings than STARPHARMA HOLD/S.
Medpace beats STARPHARMA HOLD/S on 10 of the 12 factors compared between the two stocks.
Medpace Company Profile
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
STARPHARMA HOLD/S Company Profile
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.